Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2012
Date:5/8/2012

ata at the American Society of Clinical Oncology showing that treatment with OGX-427 produced a trend toward increased tumor cell death in patients with bladder cancer and preliminary Phase 2 data showing that treatment with OGX-427 decreased prostate specific antigen in patients with metastatic prostate cancer.
  • Xenon Pharmaceuticals selected a drug targeting the hepcidin-hemojuvelin pathway as a development candidate to treat anemia of inflammation, a common form of anemia.
  • Conference Call
    At 4:30 p.m. Eastern Time today, May 8, Isis will conduct a live webcast conference call to discuss this earnings release and related activities.  Interested parties may listen to the call by dialing 866-831-6162 and refer to passcode "ISIS 2012," or access the webcast at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.

    About Isis Pharmaceuticals, Inc.
    Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

    Forward Looking Statements
    This press release includes forward-looking statements regarding Isis Pharmaceuticals' financial position and outlook, Isis' business, and the therapeutic and commercial potential of Isis' technologies and products in development, including the business of Regulus, Isis' jointly owned subsidiary.
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
    2. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
    3. Halozyme Reports First Quarter 2012 Financial Results
    4. MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results
    5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
    6. IRIDEX Reports 2012 First Quarter Results
    7. Cambrex Reports First Quarter 2012 Results
    8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    9. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
    10. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
    11. Neuland Labs Reports Financial Results For Fiscal Year 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... LAS VEGAS , July 30, 2014  DigiPath, ... provider that is expanding into the cannabis testing and ... development in its business and affairs not previously disclosed ... for the recent unusual market action. "We ... securities over the last three trading days," said ...
    (Date:7/30/2014)... , July 30, 2014 /PRNewswire-iReach/ -- This ... Global and Chinese Heparin sodium (CAS 9041-08-1) & ... the basic information of Heparin sodium (CAS 9041-08-1) ... and manufacturing technology. The report then explores global ... 9041-08-1) & calcium (CAS 37270-89-6) listing their product ...
    (Date:7/30/2014)... , July 30, 2014  PDL BioPharma, Inc. ... company management will participate in the Jefferies 2014 Boston ... , Massachusetts. The conference will occur on August 6, 2014 ... BioPharma, Inc. PDL BioPharma manages a portfolio ... Queen et al. antibody humanization patents and license agreements ...
    Breaking Medicine Technology:DigiPath No New Corporate Developments 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
    (Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 ... substantially during the five years to 2014. Following a ... thanks to beneficial demographic trends, the expansion of private ... result, IBISWorld estimates that Hearing Aid Clinics industry ... 3.4% to $2.7 billion during the five years to ...
    (Date:7/30/2014)... 2014 The global market for hearing ... 2020, growing at an estimated CAGR of 3.2% from ... Grand View Research, Inc. Growing global base of geriatric ... to serve this market as a primary growth driver. ... hearing aid technology and patient awareness levels are expected ...
    (Date:7/30/2014)... who have the most common genetic mutation linked to ... overweight or obese people who do not have the ... the Endocrine Society,s Journal of Clinical Endocrinology & ... of adults are obese. Obesity typically results from a ... activity and genetics. In particular, consumption of appetizing foods ...
    (Date:7/30/2014)... an Ohio teen who died of a caffeine overdose ... well-tolerated and mass-consumed substance. To help prevent serious health ... scientists are reporting progress toward a rapid, at-home test ... most beverages and even breast milk. Their report appears ... . , Mani Subramanian and colleagues note that caffeine,s ...
    (Date:7/30/2014)... McKinney, Texas (PRWEB) July 30, 2014 ... surgical hospital, is proud to announce the launch of ... throat (ENT), and general surgery. The doctors working in ... the needs of infants, children, and adolescents. Dr. Timothy ... Kapadia, Dr. Chad McDuffie, Dr. Neelesh Mehendale, and Dr. ...
    Breaking Medicine News(10 mins):Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3
    ... children with the most common form of childhood cancer ... the cancer cells survive their best efforts and the most ... scientists led by researchers at the University of California, San ... a protein that leukemia cells use to stay alive. Targeting ...
    ... May 18 (HealthDay News) -- Women who smoke during pregnancy ... a DNA change, a new study suggests. The change, ... researchers argue that the altered genes, which can be passed ... more likely than others to develop certain diseases, such as ...
    ... antigen) level over several years which had been seen ... recently come under fire as a screening test because it ... A new study, however, shows nearly 70 percent of ... were eventually diagnosed with prostate cancer, according to research from ...
    ... Minn. -- Mayo Clinic has developed a ... for Lynch syndrome ( http://www.mayoclinic.com/health/lynch-syndrome/DS00669 ), a ... particularly for colorectal cancer. An estimated 3 ... to Lynch syndrome. At least 80 percent ...
    ... products can be high in harmful saturated fat but not ... of thousands of adults in Costa Rica found that their ... their risk of a heart attack. "Things like milk ... community health graduate student at Brown University and the lead ...
    ... Jefferson and an international team of collaborators have discovered ... women will respond to anti-estrogen therapy. The research ... Journal of Clinical Oncology . Anti-estrogen drugs, most notably ... breast cancer. However, as many as a third of ...
    Cached Medicine News:Health News:UCSF team discovers key to fighting drug-resistant leukemia 2Health News:UCSF team discovers key to fighting drug-resistant leukemia 3Health News:When Pregnant Mom Smokes, Baby's DNA May Change 2Health News:When rising PSA means prostate cancer is in patient's future 2Health News:New Mayo Clinic test targets Lynch syndrome, a risk factor for colon cancer 2Health News:Dairy consumption does not elevate heart-attack risk, study suggests 2Health News:Marker identifies breast cancer patients likely to respond to tamoxifen 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: